Pulmonary Toxicities of Tyrosine Kinase Inhibitors

摘要: The incidence of pulmonary toxicities with the use tyrosine kinase inhibitors (TKIs) is not very high; however, various case reports and studies continue to show significant variability in these adverse events, ranging from 0.2% 10.9%. Gefitinib erlotinib are orally active, small-molecule epidermal growth factor receptor that mainly used treat non-small cell lung cancer. Imatinib an inhibitor BCR-ABL leukemias, gastrointestinal stromal tumors, other cancers. In this article, we review data identify rare but fatal (mostly interstitial disease) caused by drugs.